Clinical Trial Update: A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating AB521 as both a single agent and in combination regimens for clear cell renal cell carcinoma and other solid tumors is currently recr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma
• Solid Tumors

Drugs mentioned

• AB521

Snippet

Sponsor: Arcus Biosciences, Inc. | Conditions: Clear Cell Renal Cell Carcinoma, Solid Tumors | Phase 1 | Status: RECRUITING